Skip to content

Study · In vitro (cells) · mouse · 1996

2 results

Characterization of melanocortin receptor subtype expression in murine adipose tissues and in the 3T3-L1 cell line.

Boston BA, Cone RD

Endocrinology1 May 1996Cited by 142 (Europe PMC)

PMID8612546 (opens in a new tab)DOI10.1210/endo.137.5.8612546 (opens in a new tab)PepBankPUB-08612546
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Activity measurement

    In differentiated 3T3-L1 adipocytes, NDP-MSH acted as a potent antagonist of the MC5 receptor.

    In plain wordsIn mouse fat cells in the lab, NDP-MSH blocked the MC5 receptor instead of activating it.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    Not applicableNDP-MSH activity at the MC5 receptor in 3T3-L1 adipocytes
    Study

    mousen: not reported in source

    3T3-L1 adipocytes
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Nle4, D-Phe7-alpha-MSH (NDP-MSH), a commonly used synthetic alpha-MSH agonist, was a potent antagonist of the MC5 receptor expressed in the 3T3-L1 cell line.

Studies that did not test the peptide alone1

In this study, Melanotan I (afamelanotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Melanotan I (afamelanotide).

  1. 02LabNot a test of Melanotan I (afamelanotide) aloneIn vitro (cells)Mechanism

    In 3T3-L1 adipocytes, agouti signaling peptide did not block NDP-MSH binding. NDP-MSH served as the binding probe.

    In plain wordsIn mouse fat cells in the lab, agouti peptide did not stop NDP-MSH from binding.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    No significant changeAgouti block of NDP-MSH binding in 3T3-L1 adipocytes
    Study

    mousen: not reported in source

    3T3-L1 adipocytes
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    Although the agouti signaling peptide is a potent antagonist of NDP-MSH binding to the MC1 and MC4 melanocortin receptors, agouti was unable to block NDP-MSH binding in the 3T3-L1 adipocyte.

    In this study, Melanotan I (afamelanotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan I (afamelanotide).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.